BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38626859)

  • 1. Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade.
    Choi Y; Seok SH; Yoon HY; Ryu JH; Kwon IC
    Adv Drug Deliv Rev; 2024 Jun; 209():115306. PubMed ID: 38626859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
    Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ
    Front Immunol; 2022; 13():872295. PubMed ID: 35634282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
    Borcherding N; Kolb R; Gullicksrud J; Vikas P; Zhu Y; Zhang W
    J Mol Biol; 2018 Jul; 430(14):2014-2029. PubMed ID: 29800567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photothermal therapies to improve immune checkpoint blockade for cancer.
    Balakrishnan PB; Sweeney EE; Ramanujam AS; Fernandes R
    Int J Hyperthermia; 2020 Dec; 37(3):34-49. PubMed ID: 33426992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conserved immuno-collagenic subtypes predict response to immune checkpoint blockade.
    Mei J; Cai Y; Xu R; Li Q; Chu J; Luo Z; Sun Y; Shi Y; Xu J; Li D; Liang S; Jiang Y; Liu J; Qian Z; Zhou J; Wan M; Yang Y; Zhu Y; Zhang Y; Yin Y
    Cancer Commun (Lond); 2024 May; 44(5):554-575. PubMed ID: 38507505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.
    Mainini F; Eccles MR
    Molecules; 2020 Jun; 25(11):. PubMed ID: 32532030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.
    Piening A; Ebert E; Khojandi N; Alspach E; Teague RM
    Front Immunol; 2022; 13():1022732. PubMed ID: 36582225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano-Delivery Systems for Enhanced Immunotherapy.
    Huang X; Zhang W
    Small Methods; 2023 Dec; ():e2301326. PubMed ID: 38040834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.
    Liao L; Xu H; Zhao Y; Zheng X
    Front Med; 2023 Oct; 17(5):805-822. PubMed ID: 37897562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
    Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.
    Heinhuis KM; Ros W; Kok M; Steeghs N; Beijnen JH; Schellens JHM
    Ann Oncol; 2019 Feb; 30(2):219-235. PubMed ID: 30608567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities.
    Konen JM; Wu H; Gibbons DL
    Trends Pharmacol Sci; 2024 Jun; 45(6):520-536. PubMed ID: 38744552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boosting Checkpoint Immunotherapy with Biomimetic Nanodrug Delivery Systems.
    Chen W; Tang C; Chen G; Li J; Li N; Zhang H; Di L; Wang R
    Adv Healthc Mater; 2024 Jun; 13(14):e2304284. PubMed ID: 38319961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
    Pennock GK; Chow LQ
    Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
    Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
    J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.